Ranbaxy Laboratories today announced the launch of its branded product, Osonide (Ciclesonide) Inhaler, for the treatment of asthma.According to a release issued by Ranbaxy to the BSE today, Osonide is available in HFA (hydroxy fluoro alkane propellant) based pressurised metered dose inhalers in two strengths- Osonide 160meg and Osonide 80 meg."Osonide HFA Inhaler, as opposed to conventional CFC ( chloro fluoro carbon propellant) inhaler, is environment-friendly and ensures better delivery in patients airways with the unique property of being activated only in the lungs, thereby reducing the side effects. Along with its convenient once-a-day dosage regimen (others are twice a day), the product will ensure patient efficacy and compliance that is critical in any chronic therapy," the release added.
